References
Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer 2000; 1: 43–51
Body JJ, editor. Tumor bone disease and osteoporosis in cancer patients. New York: Marcel Dekker, 2000
Coleman RE. Metastatic bone disease: clinical fractures, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165–76
Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19: 3434–7
Banerjee D, Asif A, Striker L, et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003; 41: E18
Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676–9
Novartis Pharma. Zometa® (zoledronic acid). Prescribing information
Novartis Pharma. Aredia® (pamidronate). Prescribing information
Major P, Lipton A, Berenson J, et al. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 2000; 88: 6–14
Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59–65
Atula S, Powles T, Paterson A, et al. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf 2003; 26: 661–71
Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–5
Body JJ, Diel IJ, Lichinitser M, et al. Intravenous ibandronic acid reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399–405
Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133–7
Body JJ, Diel IJ, Bell R, et al. Oral Ibandronic acid improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111: 316–2
Tripathy D, Lichinitzer M, Lazarev A, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 2004; 15: 743–50
Cancer Therapy Evaluation Program, Common Toxicity Criteria Version 2.0, DCTD, NCI, NIH, DHHS [online]. 1999 Apr 30 Available from URL: http://ctep.cancer.gov/reporting/CTC-3test.html
Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219–24
Pecherstorfer M, Diel IJ, Bergström B. Long-term (4-year) safety of intravenous ibandronate in metastatic breast cancer: an open-label study [abstract]. Eur J Cancer Suppl 2004; 2: 130
Body JJ, Diel I, Tripathy D, et al. Impact of ibandronic acid on bone pain in patients with metastatic bone disease from breast cancer [abstract no. A-34]. Support Care Cancer 2003; 11: 395–6
Tripathy D, Pecherstorfer M, Bartl R, et al. Reduction in risk of skeletal events with ibandronic acid in the treatment of metastatic breast cancer [abstract no. A-152]. Support Care Cancer 2003; 11: 427
Navarro RP, Morrow T, Baran R. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Manag Care Interface 2002; 15: 55–62
De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronic acid versus i.v. zoledronic acid and i.v. pamidronate in the treatment of metastatic bone disease in breast cancer [abstract no. 189P]. Ann Oncol 2004; 15Suppl. 3: iii50
Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92: 1869–76
O’Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002; 87: 933–7
Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 2427–30
Paterson AHG. Adjuvant bisphosphonate therapy: the future. Semin Oncol 2001; 28: 81–5
Diel IJ, Solomayer EF, Costa S, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357–63
Green JR. Antitumor effects of bisphosphonates. Cancer Suppl 2003; 97: 840–7
Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99: 2509–17
Acknowledgements
The clinical trial and data analysis were conducted by Roche. The authors would like to thank Thomson Gardiner-Caldwell US for their editorial support.
Dr Tripathy has acted as a paid consultant for and has received honoraria and clinical research funding from Roche. Drs McLachlan, Cameron and Murray have acted as consultants for Roche.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McLachlan, SA., Cameron, D., Murray, R. et al. Safety of Oral Ibandronate in the Treatment of Bone Metastases from Breast Cancer. Clin. Drug Investig. 26, 43–48 (2006). https://doi.org/10.2165/00044011-200626010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200626010-00006